

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

REC'D 28 MAY 2004

WIPO

PCT

PCT / SE 2004 / 000738

13-05-2004

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0301446-1
Patent application number

(86) Ingivningsdatum 2003-05-16
Date of filing

Stockholm, 2004-03-11

För Patent- och registreringsverket
For the Patent- and Registration Office



Hjordis Segerlund

Avgift
Fee 170:-

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

FIELD OF THE INVENTION

The present invention relates to new compounds; to pharmaceutical formulations
5 containing said compounds and to the use of said compounds in therapy. The present
invention further relates to processes for the preparation of said compounds and to the use
of intermediates in the preparation thereof.

10 BACKGROUND OF THE INVENTION

Pain sensation in mammals is due to the activation of the peripheral terminals of a
specialized population of sensory neurons known as nociceptors. Capsaicin, the active
ingredient in hot peppers, produces sustained activation of nociceptors and also produces a
15 dose-dependent pain sensation in humans. Cloning of the vanilloid receptor 1 (VR1 or
TRPV1) demonstrated that VR1 is the molecular target for capsaicin and its analogues.
(Caterina, M.J., Schumacher, M.A., et.al. Nature 1997 v.389 p 816-824). Functional studies
using VR1 indicate that it is also activated by noxious heat and that the threshold for
activation can be lowered below normal body temperature by a reduction of the
20 extracellular pH value (acidification) and by other inflammatory mediators Tominaga, M.,
Caterina, M.J. et.al. Neuron 1998 v.21, p.531-543). Expression of VR1 is also regulated
after peripheral nerve damage of the type that leads to neuropathic pain. These properties
of VR1 make it a highly relevant target for pain and for diseases involving inflammation.
Agonists of the VR1 receptor can act as analgesics, but the usefulness of agonists, such as
25 capsaicin and its analogues, is limited by their pungency, neurotoxicity and induction of
hypothermia. Pain-evoking stimuli activate the VR1 receptor and agents that block the
activity of VR1 have also shown analgesic activity in animals.


Compounds with VR1 blocker activity are believed to be of potential use for the treatment
or prophylaxis of disorders such as pain, especially that of inflammatory or traumatic
30 origin such as arthritis, fibromyalgia, low back pain and post-operative pain. (Walker et al
J Pharmacol Exp Ther. 2003 Jan; 304(1):56-62), or visceral pains such as chronic pelvic
pain, cystitis, irritable bowel syndrome (IBS), pancreatitis and the like, and also

neuropathic pain such as sciatica, diabetic neuropathy and HIV neuropathy, and the like (Walker et al *ibid*, Rashid et al J Pharmacol Exp Ther. 2003 Mar;304(3):940-8). These compounds are also believed to be potentially useful for inflammatory disorders like asthma, cough, inflammatory bowel disease (IBD) (Hwang and Oh Curr Opin Pharmacol 2002 Jun; 2(3):235-42). Compounds with VR1 blocker activity are also useful for itch and skin diseases like psoriasis and for gastro-esophageal reflux disease (GERD), emesis, urinary incontinence and hyperactive bladder (Yiangou et al BJU Int 2001 Jun; 87(9): 774-9, Szallasi Am J Clin Pathol 2002 118: 110-21). VR1 inhibitors are also of potential use for the treatment or prophylaxis of the effects of exposure to VR1 activators like capsaicin or tear gas, acids or heat (Szallasi *ibid*).

DETAILED DESCRIPTION OF THE INVENTION

The object of the present invention is to provide compounds exhibiting an activity at the vanilloid receptor 1 (VR1).

The present invention provides a compound of formula I



wherein:

R^1 is H, NO_2 , NH_2 , halo, NR^6R^7 , $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{1-6}\text{haloalkylO}$, $\text{C}_{1-6}\text{alkylOC}_{0-6}\text{alkyl}$, $\text{R}^6\text{OC}_{1-6}\text{alkyl}$, R^6CO , CO_2R^6 or CONR^6R^7 ;

m is 1, 2, 3 or 4;

R^2 is H, NO_2 , NH_2 , halo, NR^6R^7 , $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{1-6}\text{haloalkylO}$, $\text{C}_{1-6}\text{alkylOC}_{0-6}\text{alkyl}$, $\text{R}^6\text{OC}_{1-6}\text{alkyl}$, R^6CO , CO_2R^6 or CONR^6R^7 ;

X , Y and Z are each independently C, CR^6 , N or NR^6 ;

R^3 is H or C_{0-4} alkyl;

n is 0, 1, 2 or 3;

R^4 is H or C_{0-4} alkyl;

R^5 is H, C_{1-10} alkyl, C_{5-6} aryl, C_{3-7} cycloalkyl, C_{5-6} heteroaryl, whereby any aryl or cycloalkyl
5 may be fused with heteroaryl, C_{3-7} cycloalkyl or C_{3-7} heterocycloalkyl;

and R^4 and R^5 may be substituted with one or more A; and

A is H, OH, NO_2 , NH_2 , CO, O(CO), halo, C_{1-6} alkyl, NR^6R^7 , C_{1-6} haloalkyl,

C_{1-6} alkylOC $_{0-6}$ alkyl, R^6OC_{1-6} alkyl, R^6CO , CO_2R^6 or $CONR^6R^7$;

R^6 and R^7 are each independently H or C_{1-6} alkyl;

10 or salts, solvates or solvated salts thereof,

with the proviso the compound is not 2-Indol-1-yl-N-(3-trifluoromethyl-phenyl)-acetamide
and 2-(7-Nitro-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide.

One embodiment of the invention relates to the compound of formula I wherein R^1 is H,
15 halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl;

m is 1 or 2;

R^2 is H, NO_2 , NH_2 , halo, NR^6R^7 , C_{1-6} alkyl or C_{1-6} haloalkyl;

X, Y and Z are each independently C, N and NR^6 ;

R^3 is H or C_{0-4} alkyl;

20 n is 0, 1 or 2;

R^4 is H;

R^5 is H, C_{1-10} alkyl, C_{5-6} aryl, whereby any aryl may be fused with heteroaryl;

and R^4 and R^5 may be substituted with one or more A; and

A is H, OH, halo, C_{1-6} alkyl, NR^6R^7 , C_{1-6} haloalkyl or C_{1-6} alkylOC $_{0-6}$ alkyl;

25 R^6 and R^7 are each independently H or C_{1-6} alkyl.

The number of substituents of R^1 is designated by the term m. The substituent R^1 is
selected from the group consisting of H, NO_2 , NH_2 , halo, NR^6R^7 , C_{1-6} alkyl, C_{2-6} alkenyl,
 C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} haloalkylO, C_{1-6} alkylOC $_{0-6}$ alkyl, R^6OC_{1-6} alkyl, R^6CO ,
30 CO_2R^6 or $CONR^6R^7$.

In one embodiment of the invention R^1 is selected from the group consisting of H, halo,
 C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl and C_{1-6} haloalkyl and m is 1 or 2.

R^2 may be selected from the group consisting of H, NO_2 , NH_2 , halo, NR^6R^7 , $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{1-6}\text{haloalkylO}$, $\text{C}_{1-6}\text{alkylOC}_{0-6}\text{alkyl}$, $\text{R}^6\text{OC}_{1-6}\text{alkyl}$, R^6CO , CO_2R^6 and CONR^6R^7 .

5 In one embodiment of the invention R^2 is H, NO_2 , NH_2 or halo.

X, Y and Z are atoms in an aromatic 5-membered ring as shown in the structure of the compound of formula I.

In one embodiment of the invention X, Y and Z are independently selected from the group
10 consisting of C, CR^6 , N and NR^6 .

In another embodiment of the invention X and Z are N and Y is CR^6 .

R^3 may be H or $\text{C}_{0-4}\text{alkyl}$. In one embodiment of the invention R^3 is H.

15 The length of the alkyl chain in the structure of formula I is designated by the term n. n may be 0, 1, 2 or 3. In one embodiment of the invention n is 0.

R^4 and R^5 are substituents on the nitrogen atom. In one embodiment of the invention R^4 is H or $\text{C}_{0-4}\text{alkyl}$ and R^5 is selected from the group consisting of H, $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{5-6}\text{aryl}$,
20 $\text{C}_{3-7}\text{cycloalkyl}$ and $\text{C}_{5-6}\text{heteroaryl}$, whereby any aryl or cycloalkyl may be fused with heteroaryl, $\text{C}_{3-7}\text{cycloalkyl}$ and $\text{C}_{3-7}\text{heterocycloalkyl}$.

In another embodiment of the invention R^4 is H and R^5 is selected from the group consisting of H, $\text{C}_{1-10}\text{alkyl}$ and $\text{C}_{5-6}\text{aryl}$, whereby any aryl may be fused with heteroaryl.

25 Further, R^4 and R^5 may be substituted with one or more A.

In one embodiment of the invention A is selected from the group consisting of H, OH, NO_2 , NH_2 , CO, $\text{O}(\text{CO})$, halo, $\text{C}_{1-6}\text{alkyl}$, NR^6R^7 , $\text{C}_{1-6}\text{haloalkyl}$, $\text{C}_{1-6}\text{alkylOC}_{0-6}\text{alkyl}$, $\text{R}^6\text{OC}_{1-6}\text{alkyl}$, R^6CO , CO_2R^6 and CONR^6R^7 .

In another embodiment of the invention A is selected from the group consisting of H, halo,
30 $\text{C}_{1-6}\text{alkyl}$, NR^6R^7 , $\text{C}_{1-6}\text{haloalkyl}$ and $\text{C}_{1-6}\text{alkylOC}_{0-6}\text{alkyl}$.

A further embodiment of the invention relates to compounds selected from the group consisting of

- 2-Benzoimidazol-1-yl-*N*-(3-trifluoromethyl-phenyl)-propionamide,
2-Benzoimidazol-1-yl-*N*-(3-chloro-4-fluoro-phenyl)-acetamide,
5 2-Benzoimidazol-1-yl-*N*-(3-fluoro-4-methyl-phenyl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(3,4-difluoro-phenyl)-acetamide,
2-(4-Methyl-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(4,5-Difluoro-benzoimidazol-1-yl)-*N*-(3-trifluoromethyl-phenyl)-acetamide,
2-(6,7-difluoro-benzoimidazol-1-yl)-*N*-(3-trifluoromethyl-phenyl)-acetamide,
10 2-(4,5-difluoro-benzoimidazol-1-yl)-*N*-(3-trifluoromethyl-phenyl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(3-dimethylamino-phenyl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(4-tert-butyl-phenyl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(3-trifluoromethyl-benzyl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(4-chloro-benzyl)-acetamide,
15 2-(1*H*-Benzoimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
3-Benzoimidazol-1-yl-*N*-(4-tert-butyl-phenyl)-propionamide,
4-Benzoimidazol-1-yl-*N*-(4-tert-butyl-phenyl)-butyramide,
2-Benzoimidazol-1-yl-*N*-(2-methyl-benzothiazol-5-yl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(3-trifluoromethyl-phenyl)-acetamide,
20 2-(4-Amino-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(6,7-Difluoro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(5-fluoro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(6-fluoro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(1*H*-benzoimidazol-1-yl)-*N*-heptylacetamide,
25 2-(5-Fluoro-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, and
2-(1-Methyl-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
or salts, solvates or solvated salts thereof.

Listed below are definitions of various terms used in the specification and claims to
30 describe the present invention.

For the avoidance of doubt it is to be understood that where in this specification a group is qualified by 'hereinbefore defined', 'defined hereinbefore' or 'defined above' the said group encompasses the first occurring and broadest definition as well as each and all of the other definitions for that group.

For the avoidance of doubt it is to be understood that in this specification 'C₁₋₆' means a carbon group having 1, 2, 3, 4, 5 or 6 carbon atoms.

In this specification, unless stated otherwise, the term "alkyl" includes both straight and branched chain alkyl groups and may be, but are not limited to methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl. The term C₁₋₃ alkyl having 1 to 3 carbon atoms and may be methyl, ethyl, n-propyl, i-propyl or *tert*-butyl.

The term 'C₀' means a bond or does not exist. For example when R³ is C₀alkyl, R³ is a bond and "arylC₀alkyl" is equivalent with "aryl", "C₂alkylOC₀alkyl" is equivalent with "C₂alkylO".

In this specification, unless stated otherwise, the term "alkenyl" includes both straight and branched chain alkenyl groups. The term "C₂₋₆alkenyl" having 2 to 6 carbon atoms and one or two double bonds, may be, but is not limited to vinyl, allyl, propenyl, butenyl, crotyl, pentenyl, or hexenyl, and a butenyl group may for example be buten-2-yl, buten-3-yl or buten-4-yl.

In this specification, unless stated otherwise, the term "alkynyl" includes both straight and branched chain alkynyl groups. The term "C₂₋₆alkynyl" having 2 to 6 carbon atoms and one or two trippel bonds, may be, but is not limited to etynyl, propargyl, pentynyl or hexynyl and a butynyl group may for example be butyn-3-yl or butyn-4-yl.

In this specification, unless stated otherwise, the term "cycloalkyl" refers to an optionally substituted, saturated cyclic hydrocarbon ring system. The term "C₃₋₇cycloalkyl" may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

The term "heterocycloalkyl" denotes a 3- to 7-membered, non-aromatic, partially or completely saturated hydrocarbon group, which contains one rings and at least one heteroatom. Examples of said heterocycle include, but are not limited to pyrrolidinyl, pyrrolidonyl, piperidinyl, piperazinyl, morpholinyl, oxazolyl, 2-oxazolidonyl or tetrahydrofuranyl.

In this specification, unless stated otherwise, the term "aryl" refer to an optionally substituted monocyclic or bicyclic hydrocarbon unsaturated aromatic ring system.

Examples of "aryl" may be, but are not limited to phenyl and naphthyl.

In this specification, unless stated otherwise, the term "heteroaryl" refer to an optionally substituted monocyclic or bicyclic unsaturated aromatic ring system containing at least one heteroatom selected independently form N, O or S. Examples of "heteroaryl" may be, but are not limited to pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, benzofuryl, indolyl, isoindolyl, benzimidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrazolyl, triazolyl and oxazolyl.

In this specification, unless stated otherwise, the term "arylalkyl" and "heteroarylalkyl" refer to a substituent that is attached via the alkyl group to an aryl or heteroaryl group.

In this specification, unless stated otherwise, the term "halo" and "halogen" may be fluoro, iodo, chloro or bromo.

In this specification, unless stated otherwise, the term "haloalkyl" means an alkyl group as defined above, which is substituted with halo as defined above. The term "C₁₋₆haloalkyl" may include, but is not limited to fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl or bromopropyl. The term "C₁₋₆haloalkylO" may include, but is not limited to fluoromethoxy, difluoromethoxy, trifluoromethoxy, fluoroethoxy or difluoroethoxy.

The present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts, solvates or solvated salts thereof. Salts for use in pharmaceutical formulations will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I.

5 A suitable pharmaceutically acceptable salt of the compounds of the invention is, for example, an acid-addition salt, for example an inorganic or organic acid. In addition, a suitable pharmaceutically acceptable salt of the compounds of the invention is an alkali metal salt, an alkaline earth metal salt or a salt with an organic base.

Other pharmaceutically acceptable salts and methods of preparing these salts may be found
10 in, for example, Remington's Pharmaceutical Sciences (18th Edition, Mack Publishing Co.).

Some compounds of formula I may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such
15 optical, diastereoisomeric and geometric isomers.

The invention also relates to any and all tautomeric forms of the compounds of formula I.

Methods of Preparation

20 Another aspect of the present invention provides processes for preparing compounds of formula I, or salts, solvates or solvated salts thereof.

Throughout the following description of such processes it is to be understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from,
25 the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are described, for example, in "Protective Groups in Organic Synthesis", T.W. Green, P.G.M. Wuts, Wiley-Interscience, New York, (1999). References and descriptions of other suitable reactions are described in
30 textbooks of organic chemistry, for example, "Advanced Organic Chemistry", March, 4th ed. McGraw Hill (1992) or, "Organic Synthesis", Smith, McGraw Hill, (1994). For representative examples of heterocyclic chemistry see for example "Heterocyclic


Chemistry", J. A. Joule, K. Mills, G. F. Smith, 3rd ed. Chapman and Hall (1995), p. 189-224 and "Heterocyclic Chemistry", T. L. Gilchrist, 2nd ed. Longman Scientific and Technical (1992), p. 248-282.

The term "room temperature" and "ambient temperature" shall mean, unless otherwise specified, a temperature between 16 and 25 °C.

One embodiment of the invention relates to processes for the preparation of the compound of formula I according to Methods A and B, wherein R¹ to R⁴, unless otherwise specified, are defined as in formula I, comprising;

Another object of the invention are processes for the preparation of the compound of formula I wherein R¹ to R⁵, unless otherwise specified, are defined as in formula I, comprising;

Method A




whereby the target compound of formula Ia is obtained from the acid of formula IIa or its deprotonated form IIb, *via* its conversion into an activated form, i.e. either the acyl chloride by treatment with oxalyl chloride or the mixed anhydride by treatment with *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate and further treatment with an appropriate amine NHR⁴R⁵. This reaction may be performed in any manner known to the skilled man in the art.

The activation may be performed using any other similar activating reagent like 1,3-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or 1,1'-carbonyldiimidazole. Suitable solvents to be used for this reaction may be halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane or aromatic and heteroaromatic compounds such as benzene, toluene, xylene, pyridine and lutidine or ethers such as ethyl ether, tetrahydrofuran and dioxan or any mixtures thereof. Catalysts such as heteroaromatic bases like pyridine and lutidine or tertiary amines like triethylamine, *N*-methylmorpholine and ethyl diisopropylamine may be used as well. The temperature may be between -30 and 50°C and the reaction time between 1 and 30 h.

The intermediate acids of formula IIa may be obtained using 2-steps procedure according to which benzoimidazole of formula III will be alkylated with an appropriate alkylbromide to give an ester of formula IV, and the latter may be deprotected by treatment with trifluoroacetic acid (and optionally converted to the anionic form IIb).

Or,

Method B




wherein, the target compound of formula Ia is obtained from an alkylbromide of formula V and an appropriate benzimidazole. Suitable solvents to be used for this reaction may be tertiary amides such as dimethylformamide or dimethylacetamide or aromatic compounds such as benzene, toluene and xylene, or ethers such as ethyl ether, tetrahydrofuran and dioxan or alcohols such as methanol, ethanol and propanol, or any mixtures thereof. Bases such as potassium tert-butoxide, sodium methoxide and sodium hydride or tertiary amines like triethylamine, *N*-methylmorpholine and ethyl diisopropylamine may be used as well. The temperature may be between 0 and 100°C and the reaction time between 1 and 30 h. The intermediate alkylbromides of formula V may be obtained by amination of the corresponding acyl bromides of formula VI.

Substituted benzimidazoles employed in Methods A and B are generally expected to yield mixtures of regioisomers I which in some cases may be separated into pure individual components. This is exemplified in Method C.

- 5 One embodiment of the invention relates to a process for purifying mixtures of regioisomers of the compound of formula I, comprising;

Method C



10 wherein 4-nitrobenzimidazole is converted to a mixture of 4-nitro- and 7-nitro-regioisomers of formula Ib and Ic, or the nitro derivative is converted to the corresponding amino derivative of formula Id using an appropriate reducing agent.

A further embodiment of the invention relates to compounds
 2-bromo-N-(3-trifluoromethyl-phenyl)-propionamide,
 15 benzimidazol-1-yl-acetic acid *tert*-butyl ester,
 3-carboxymethyl-3*H*-benzimidazol-1-ium trifluoro-acetate,

2-bromo-*N*-(3-trifluoromethyl-phenyl)-acetamide,

Synthesis of 4-methyl-1*H*-benzoimidazole,

2-Bromo-*N*-(3-dimethylamino-phenyl)-acetamide,

methyl 3-(1*H*-benzoimidazol-1-yl)propanoate ,

5 3-(1*H*-benzoimidazol-1-yl)propanoic acid,

methyl 4-(1*H*-benzoimidazol-1-yl)butanoate, and

4-(1*H*-benzoimidazol-1-yl)butanoic acid,

which may be used as intermediates in the preparation of compounds suited for the treatment of VR1 mediated disorders, especially for use as intermediates for the

10 preparation of compounds of formula I.

Pharmaceutical formulation

According to one aspect of the present invention there is provided a pharmaceutical
15 formulation comprising as active ingredient a therapeutically effective amount of the compound of formula I, or salts, solvates or solvated salts thereof, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.

The composition may be in a form suitable for oral administration, for example as a tablet,
20 pill, syrup, powder, granule or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration e.g. as an ointment, patch or cream or for rectal administration e.g. as a suppository.

In general the above compositions may be prepared in a conventional manner using one or
25 more conventional excipients, pharmaceutical acceptable diluents and/or inert carriers.

Suitable daily doses of the compound of formula I in the treatment of a mammal, including man are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and about 0.001 to 250 mg/kg bodyweight at parenteral administration. The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the
30 relevant indication, severity of the illness being treated, the route of administration, the age, weight and sex of the patient and the particular compound being used, and may be determined by a physician.

Medical use

Surprisingly, it has been found that the compounds according to the present invention are
5 useful in therapy. The compounds of formula I, or salts, solvates or solvated salts thereof,
as well as their corresponding active metabolites, exhibit a high degree of potency and
selectivity for individual vanilloid receptor 1 (VR1) groups. Accordingly, the compounds
of the present invention are expected to be useful in the treatment of conditions associated
with excitatory activation of vanilloid receptor 1 (VR1).

10 The compounds may be used to produce an inhibitory effect of VR1 in mammals,
including man.

VR1 are highly expressed in the peripheral nervous system and in other tissues.

Thus, it is expected that the compounds of the invention are well suited for the
treatment of VR1 mediated disorders. The compounds of formula I are expected to
15 be suited for the treatment of acute and chronic pain and acute and chronic
inflammatory pain. The compound may further be suited for the treatment of chronic
neuropathic pain.

Examples of such disorder may be selected from the group comprising of arthritis,
fibromyalgia, low back pain, post-operative pain, visceral pains like chronic pelvic pain,
20 cystitis, irritable bowel syndrome (IBS), pancreatitis, sciatica, diabetic neuropathy, HIV
neuropathy, asthma, cough, inflammatory bowel disease (IBD) and psoriasis.

Further relevant disorders that may be treated using the compounds of formula I may be
selected from the group comprising of gastro-esophageal reflux disease (GERD), emesis,
urinary incontinence and hyperactive bladder.

25 The compounds of formula I may also be used as antitoxin to treat (over-) exposure
to VR1 activators like capsaicin or tear gas, acids or heat.

The compounds may further be used for treatment of tolerance to VR1 activators.

30 One embodiment of the invention relates to the use of the compound of formula I in
therapy.

Another embodiment of the invention relates to the use of the compound of formula I for treatment of VR1 mediated disorders.

A further embodiment of the invention relates to the use of the compound of formula I for
5 treatment of acute and chronic pain disorders

Yet another embodiment of the invention relates to the use of the compound of formula I for treatment of acute and chronic inflammatory pain.

10 Yet a further embodiment of the invention relates to the use of the compound of formula I as hereinbefore defined, for treatment of indications selected from the group consisting of arthritis, fibromyalgia, low back pain, post-operative pain, visceral pains like chronic pelvic pain, cystitis, IBS, pancreatitis, sciatica, diabetic neuropathy, HIV neuropathy, asthma, cough, IBD, psoriasis, gastro-esophageal reflux disease (GERD), emesis, urinary
15 incontinence and hyperactive bladder.

One embodiment of the invention relates to the use of the compound of formula I as hereinbefore defined, in the manufacture of a medicament for the treatment of VR1 mediated disorders and for the treatment of acute and chronic pain disorders and acute and
20 chronic inflammatory pain and any other disorder mentioned above.

Another embodiment of the invention relates to a method of treatment of VR1 mediated disorders and acute and chronic pain disorders and acute and chronic inflammatory pain and any other disorder mentioned above, comprising administering to a mammal,
25 including man in need of such treatment, a therapeutically effective amount of the compound of formula I, as hereinbefore defined.

A further embodiment of the invention relates to a pharmaceutical formulation comprising the compound of formula I, as hereinbefore defined, for use in the treatment of VR1
30 mediated disorders and for the treatment of acute and chronic pain disorders and acute and chronic inflammatory pain and any other disorder mentioned above.

One embodiment of the invention relates to the use of 2-Indol-1-yl-*N*-(3-trifluoromethyl-phenyl)-acetamide and 2-(7-Nitro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, in the manufacture of a medicament for the treatment of VR1 mediated disorders and for the treatment of acute and chronic pain disorders and
5 acute and chronic inflammatory pain and any other disorder mentioned above.

Another embodiment of the invention relates to a method of treatment of VR1 mediated disorders and acute and chronic pain disorders and acute and chronic inflammatory pain and any other disorder mentioned above, comprising administering to a mammal,
10 including man in need of such treatment, a therapeutically effective amount of 2-Indol-1-yl-*N*-(3-trifluoromethyl-phenyl)-acetamide or 2-(7-Nitro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide.

A further embodiment of the invention relates to a pharmaceutical formulation comprising
15 2-Indol-1-yl-*N*-(3-trifluoromethyl-phenyl)-acetamide or 2-(7-Nitro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, for use in the treatment of VR1 mediated disorders and for the treatment of acute and chronic pain disorders and acute and chronic inflammatory pain and any other disorder mentioned above.

20 In the context of the present specification, the term "therapy" and "treatment" includes prevention and prophylaxis, unless there are specific indications to the contrary. The terms "treat", "therapeutic" and "therapeutically" should be construed accordingly.

25 In this specification, unless stated otherwise, the term "antagonist" and "inhibitor" mean a compound that by any means, partly or completely, blocks the transduction pathway leading to the production of a response by the ligand.

The term "disorder", unless stated otherwise, means any condition and disease associated with vanilloid receptor activity.
30

Non- Medical use

In addition to their use in therapeutic medicine, the compounds of formula I, or salts, solvates or solvated salts thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of VR1 related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.

Examples

The invention will now be illustrated by the following non-limiting examples.

General methods

All starting materials are commercially available or described in the literature. The ¹H NMR spectra were recorded on Bruker at 400 MHz. The mass spectra were recorded utilising electrospray (LC-MS; LC: Waters 2790, column XTerra MS C₈ 2.5 µm 2.1X30 mm, buffer gradient H₂O+0.1%TFA:CH₃CN+0.04%TFA, MS: micromass ZMD// ammonium acetate buffer) ionisation techniques.

Example 1

2-Benzoimidazol-1-yl-N-(3-trifluoromethyl-phenyl)-propionamide

Part A: Synthesis of 2-bromo-N-(3-trifluoromethyl-phenyl)-propionamide

2-Bromopropionyl bromide (430 mg, 2.1 mmol) was added under stirring to a solution of 3-trifluoromethyl-aniline (320 mg, 2.0 mmol) and triethylamine (0.3 mL, 2.1 mmol) in dichloromethane (15 mL). The reaction was stirred for 1 h at ambient temperature and the solvent was evaporated. The crude product was purified by flash chromatography (silica, 20% heptane in ethyl acetate) to afford 2-bromo-N-(3-trifluoromethyl-phenyl)-propionamide (0.50 g, 85%).

Mass spectrum (ESI) m/z: 296.9, 297.9.

¹H NMR (400 MHz, CDCl₃) δ ppm 2.0 (d, *J*=7.1 Hz, 3 H), 4.5 (q, *J*=7.1 Hz, 1 H), 7.4 (d, *J*=7.6 Hz, 1 H), 7.5 (t, *J*=7.8 Hz, 1 H), 7.7 (d, *J*=7.9 Hz, 1 H), 7.8 (s, 1 H), 8.2 (s, 1 H).

Part B: Synthesis of the title compound

5 A solution of potassium *tert*-butoxide (0.25 mL of 1 M solution in THF, 0.25 mmol) was added to a solution of 1*H*-benzoimidazole (30 mg, 0.25 mmol) in anhydrous dioxane (10 mL) and anhydrous DMF (1 mL) under argon at ambient temperature. The mixture was stirred for 5 min before a solution of bromo-*N*-(3-trifluoromethyl-phenyl)-propionamide (59 mg, 0.2 mmol) in anhydrous dioxane (3 mL) was added. The mixture was stirred for 4
10 h, filtered and concentrated in vacuum. The crude product was purified on a preparative HPLC (XTerra C₈ column 19×300 mm, 0.1 M aqueous NH₄Ac/CH₃CN). Product-containing fractions were pooled and lyophilized to afford 40 mg (60%) of the title compound.

¹H NMR (400 MHz, CDCl₃) δ ppm 1.8 (d, *J*=7.1 Hz, 3 H), 5.1 (q, *J*=7.4 Hz, 1 H), 7.2 (m, 4 H), 7.4 (d, *J*=7.1 Hz, 1 H), 7.5 (m, 2 H), 7.7 (m, 1 H), 7.9 (s, 1 H), 10.2 (s, 1 H).
15

Example 2

2-Benzoimidazol-1-yl-*N*-(3-chloro-4-fluoro-phenyl)-acetamide

Part A: Synthesis of benzoimidazol-1-yl-acetic acid *tert*-butyl ester

20 A solution of potassium *tert*-butoxide (0.6 mmol) in THF (0.6 mL) was added to a solution of 1*H*-benzoimidazole (71 mg, 0.6 mmol) in dioxane (15 mL) under stirring. *tert*-Butyl bromoacetate (97 mg, 0.5 mmol) was added to the white suspension and the mixture was stirred overnight at ambient temperature. The solvents were removed in vacuum and the product was purified on a silica gel column using a gradient of ethyl acetate in heptane) to
25 afford benzoimidazol-1-yl-acetic acid *tert*-butyl ester (110 mg, 95%).

Mass spectrum (ESI) *m/z*: 233.0.

¹H NMR (400 MHz, MeOD) δ ppm 1.5 (s, 9 H), 5.0 (s, 2 H), 7.3 (m, 2 H), 7.4 (d, *J*=7.1 Hz, 1 H), 7.7 (d, *J*=6.6 Hz, 1 H), 8.1 (s, 1 H).

30 **Part B: Synthesis of 3-carboxymethyl-3*H*-benzoimidazol-1-ium trifluoro-acetate**

Benzoimidazol-1-yl-acetic acid *tert*-butyl ester (110 mg, 0.47 mmol) was dissolved in dichloromethane (3 mL) and trifluoroacetic acid (1 mL) was added. The reaction was

stirred at ambient temperature for 24 h and the solvents were removed to afford 3-carboxymethyl-3*H*-benzoimidazol-1-ium trifluoro-acetate (136 mg, 100%).

Mass spectrum (ESI) *m/z*: 177.0.

¹H NMR (400 MHz, MeOD) δ ppm 5.3 (s, 2 H), 7.5 (m, 2 H), 7.8 (m, 2 H), 9.4 (s, 1 H).

Part C: Synthesis of the title compound

3-Carboxymethyl-3*H*-benzoimidazol-1-ium trifluoro-acetate (128 mg, 0.44 mmol) was dissolved in a mixture of oxalyl chloride (0.6 mL) and dichloromethane (3.4 mL). The reaction mixture was stirred for 30 min at ambient temperature and the solvent was evaporated. The residue was dissolved in a mixture of dichloromethane (2.5 mL) and anhydrous THF (2.5 mL) and added to a mixture of 3-chloro-4-fluoro-aniline (17 mg, 0.12 mmol) and *N,N*-(diisopropyl)aminomethylpolystyrene resin (140 mg, Argonaut Technologies, Inc) in anhydrous THF (3 mL). The mixture was shaken overnight. The resin was filtered off, the solvents were evaporated and the crude product was purified on a preparative LC/MS (XTerra C₈ column 19×100 mm, 0.1 M aqueous NH₄Ac/CH₃CN). The pooled fractions were lyophilized to afford 7.2 mg (20%) of the title compound.

Calculated for C₁₅H₁₁ClFN₃O *m/z*: 303.7, found 304.7 [M+H]⁺.

¹H NMR (400 MHz, MeOD) δ ppm 5.2 (s, 2 H), 7.2 (t, *J*=9.1 Hz, 1 H), 7.3 (m, 2 H), 7.5 (m, 1 H), 7.5 (d, *J*=7.1 Hz, 1 H), 7.7 (d, *J*=7.1 Hz, 1 H), 7.8 (dd, *J*=6.6, 2.5 Hz, 1 H), 8.2 (s, 1 H).

Example 3

2-Benzoimidazol-1-yl-*N*-(3-fluoro-4-methyl-phenyl)-acetamide

The title compound was synthesised according to the procedure described in Example 2, from 3-carboxymethyl-3*H*-benzoimidazol-1-ium trifluoro-acetate and 3-fluoro-4-methylaniline.

Yield 12 mg (35%).

Calculated for C₁₆H₁₄FN₃O *m/z*: 283.3, found 284.3 [M+H]⁺.

¹H NMR (400 MHz, MeOD) δ ppm 2.2 (s, 3 H), 5.1 (s, 2 H), 7.1 (m, 2 H), 7.3 (m, 2 H), 7.4 (d, *J*=11.6 Hz, 1 H), 7.5 (d, *J*=8.6 Hz, 1 H), 7.7 (m, 1 H), 8.1 (s, 1 H).

Example 4***2-Benzoimidazol-1-yl-N-(3,4-difluoro-phenyl)-acetamide***

The title compound was synthesised according to the procedure described in Example 2, from 3-carboxymethyl-3H-benzoimidazol-1-ium trifluoro-acetate and 3,4-difluoroaniline

Yield 9.1 mg (26%).

Calculated for $C_{15}H_{11}F_2N_3O$ m/z : 287.2, found 288.3 $[M+H]^+$.

1H NMR (400 MHz, MeOD) δ ppm 5.2 (s, 2 H), 7.3 (m, 4 H), 7.5 (d, $J=7.1$ Hz, 1 H), 7.7 (m, 2 H), 8.2 (s, 1 H).

Example 5***2-Indol-1-yl-N-(3-trifluoromethyl-phenyl)-acetamide*****Part A: Synthesis of 2-bromo-N-(3-trifluoromethyl-phenyl)-acetamide**

Bromoacetyl bromide (1.41 g, 7 mmol) was added under stirring to a solution of 3-trifluoromethyl-aniline (0.77 g, 4.8 mmol) and triethylamine (0.83 mL, 8.2 mmol) in THF (60 mL) at 0 °C. The reaction was stirred for 3 h at 0 °C and the solvent was evaporated. The crude product was purified by flash chromatography (Silica, heptane/ethyl acetate 1:1) to afford 2-bromo-N-(3-trifluoromethyl-phenyl)-acetamide (1.35 g, 100%).

Mass spectrum (ESI) m/z : 280.0, 282.0.

1H NMR (400 MHz, DMSO- d_6) δ ppm 3.93 (s, 2 H), 7.31 (d, $J=8.1$ Hz, 1 H), 7.44 (t, $J=7.8$ Hz, 1 H), 7.63 (d, $J=8.1$ Hz, 1 H), 7.93 (s, 1 H), 10.57 (s, 1 H).

Part B: Synthesis of title compound

A solution of potassium *tert*-butoxide (0.25 mmol) in THF (0.25 mL) was added to a solution of 1H-indole (30 mg, 0.25 mmol) in a mixture of dioxane (6 mL) and DMF (1.5 mL) under argon atmosphere at ambient temperature. The solution was stirred for 5 min before a solution of 2-bromo-N-(3-trifluoromethyl-phenyl)-acetamide (0.2 mmol) in DMF (1 mL) was added dropwise. The reaction mixture was stirred overnight at ambient temperature and the solvents were removed in vacuum. The crude product was purified on a preparative LC/MS (XTerra C₈ column 19x100 mm, 0.1 M aqueous NH₄Ac/CH₃CN). The product-containing fractions were pooled and lyophilized to afford 24 mg (38 %) of the title compound.

Calculated for $C_{17}H_{13}F_3N_2O$ m/z : 318.3, found 319.0 $[M+H]^+$.

1H NMR (400 MHz, $CDCl_3$) δ ppm 4.9 (s, 2 H), 6.7 (d, $J=3.0$ Hz, 1 H), 7.0 (s, 1 H), 7.1 (d, $J=3.0$ Hz, 1 H), 7.2 - 7.3 (m, 5 H), 7.4 (m, 1 H), 7.6 (s, 1 H), 7.7 (d, $J=8.1$ Hz, 1 H).

5 Example 6

2-(4-Methyl-1H-benzoimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide

Part A: Synthesis of 4-methyl-1H-benzoimidazole

A solution of 3-methylbenzene-1,2-diamine (500 mg, 4.1 mmol) in formic acid (4.5 mL,
10 120 mmol) was irradiated in a microwave oven for 15 min at 135 °C. The reaction mixture was cooled to ambient temperature and the formic acid was removed under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and extracted with saturated aqueous $NaHCO_3$ (2×10 mL), water (10 mL) and brine (10 mL). The organic phase was dried over anhydrous Na_2SO_4 and the solvent was removed in vacuum yielding 4-methyl-
15 1H-benzoimidazole (519 mg, 96%)

Calculated for $C_8H_8N_2$ m/z : 132.07, found 133.13 $[M+H]^+$.

1H NMR (400 MHz, $DMSO-d_6$) δ ppm 2.50 (s, 3 H), 6.96 (m, 1 H), 7.06 (m, 1 H), 7.38 (d, $J=7.6$ Hz, 1 H), 8.15 (s, 1 H), 12.41 (s, 1 H).

20 Part B: Synthesis of the title compound

The title compound was synthesized in 39% yield (65 mg) according to a procedure described in Example 5, using 4-methyl-1H-benzoimidazole (66 mg, 0.5 mmol) and 2-bromo-*N*-(3-trifluoromethyl-phenyl)-acetamide (Example 5, part A) (141 mg, 0.5 mmol).

Calculated for $C_{17}H_{14}F_3N_3O$ m/z : 333.11, found 334.07 $[M+H]^+$.

25 1H NMR (400 MHz, $DMSO-d_6$) δ ppm 2.54 (s, 3 H), 5.18 (s, 2 H), 7.01 (d, $J=7.6$ Hz, 1 H), 7.12 (m, 1 H), 7.33 (d, $J=8.1$ Hz, 1 H), 7.42 (d, $J=7.6$ Hz, 1 H), 7.57 (t, $J=8.1$ Hz, 1 H), 7.77 (d, $J=8.1$ Hz, 1 H), 8.06 (s, 1 H), 8.18 (s, 1 H), 10.77 (s, 1 H).

Example 7

30 *2-(4,5-Difluoro-benzoimidazol-1-yl)-N-(3-trifluoromethyl-phenyl)-acetamide* and *2-(6,7-difluoro-benzoimidazol-1-yl)-N-(3-trifluoromethyl-phenyl)-acetamide* (mixture of 4,5- and 6,7-difluoro- regioisomers)

2-Bromo-*N*-(3-trifluoromethyl-phenyl)-acetamide (see Example 5, Part A) (29 mg, 0.1 mmol) and 4,5-difluoro-1*H*-benzimidazole (23 mg, 0.15 mmol) were added sequentially to a solution of potassium *tert*-butoxide (0.18 mL of 1 M solution in THF, 0.18 mmol,) in DMF (1.5 mL) under argon atmosphere. The reaction was stirred at ambient temperature overnight. The product was purified on a preparative LC/MS (XTerra C₈ column 19×100 mm, 0.1 M aqueous NH₄Ac/CH₃CN) affording the title compounds in 2:1 ratio. Calculated for C₁₆H₁₀F₅N₃O *m/z*: 355.27, found 356.0 [M+H]⁺.

Example 8

10 2-Benzimidazol-1-yl-*N*-(3-dimethylamino-phenyl)-acetamide

Part A: 2-Bromo-*N*-(3-dimethylamino-phenyl)-acetamide

Bromoacetyl bromide (21 μL, 0.24 mmol) was added to a suspension of *N,N*-dimethylbenzene-1,3-diamine (27 mg, 0.2 mmol) and PS-diisopropylethylamine (170 mg of the resin, 0.6 mmol) in anhydrous THF (1.5 mL). The mixture was stirred overnight at ambient temperature. The resin was filtered off and the solution containing 2-bromo-*N*-(3-dimethylamino-phenyl)-acetamide was used directly in the next step (see Part B).

Part B: The title compound was synthesised according to the procedure described in Example 7, from 2-bromo-*N*-(3-dimethylamino-phenyl)-acetamide and 1*H*-benzimidazole.

Calculated for C₁₇H₁₈N₄O *m/z*: 294.3, found 295.3 [M+H]⁺.

Example 9

2-Benzimidazol-1-yl-*N*-(4-*tert*-butyl-phenyl)-acetamide

The title compound was synthesised according to the procedure described in Example 8 (Part B), from 1*H*-benzimidazole and 2-bromo-*N*-(4-*tert*-butyl-phenyl)-acetamide. The latter was synthesized according to the procedure described in Example 8 (Part A) from bromoacetyl bromide and 4-*tert*-butyl-aniline.

Calculated for C₁₉H₂₁N₃O *m/z*: 307.3, found 308.4 [M+H]⁺.

Example 10***2-Benzoimidazol-1-yl-N-(3-trifluoromethyl-benzyl)-acetamide***

O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (80 mg, 0.21 mmol) was added under stirring to a solution of 3-carboxymethyl-3H-benzoimidazol-1-ium trifluoro-acetate (Example 2 part B) (32 mg, 0.2 mmol) and N-methyl morpholine (66 μ L, 0.6 mmol) in acetonitrile (1 mL). After 5 min 3-trifluoromethyl-benzylamine (0.2 mmol, 35 mg) was added and the mixture was shaken overnight at ambient temperature. Purification was performed on a preparative LC/MS (XTerra C₈ column 19x100 mm, 0.1 M NH₄OAc/CH₃CN). Product-containing fractions were pooled and lyophilized thus affording 8.3 mg of the title compound (12%).

Calculated for C₁₇H₁₄F₃N₃O *m/z*: 333.32, found 334.1 [M+H]⁺.

Example 11***2-Benzoimidazol-1-yl-N-(4-chloro-benzyl)-acetamide***

The title compound was synthesized according to a procedure described in Example 10 starting from 3-carboxymethyl-3H-benzoimidazol-1-ium trifluoro-acetate (Example 2, Part B) and 4-chloro-benzylamine

Calculated for C₁₆H₁₄ClN₃O *m/z*: 299.76, found 301.1 [M+H]⁺.

Example 12***2-(1H-Benzoimidazol-1-yl)-N-(3,5-dimethoxyphenyl)acetamide***

The title compound was synthesized according to a procedure described in Example 10 starting from 3-carboxymethyl-3H-benzoimidazol-1-ium trifluoro-acetate (Example 2 part B) and 3,5-dimethoxy-aniline.

Calculated for C₁₇H₁₇N₃O₃ *m/z*: 311.34, found 311.88 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.69 (s, 6 H), 5.14 (s, 2 H), 6.23 (t, *J*=2.3 Hz, 1 H), 6.82 (d, *J*=2.0 Hz, 2 H), 7.22 (m, 2 H), 7.51 (d, *J*=7.6 Hz, 1 H), 7.66 (dd, *J*=7.3, 1.3 Hz, 1 H), 8.21 (s, 1 H), 10.41 (s, 1 H).

Example 13***3-Benzoimidazol-1-yl-N-(4-tert-butyl-phenyl)-propionamide***

Part A: Synthesis of methyl 3-(1H-benzoimidazol-1-yl)propanoate

To a solution of 1*H*-benzoimidazole (1.21 g, 10 mmol) in dry DMF (30 mL) potassium *tert*-butoxide solution in THF (1 M, 10.5 mL, 10.5 mmol) was added under stirring at ambient temperature. After 15 min methyl 3-bromopropanoate (1.1 mL, 10 mmol) was added drop-wise and the reaction mixture was stirred for 16 h. The mixture was quenched by addition of methanol (1 mL) and formic acid (1 mL), and concentrated in vacuum. The residue was treated with a mixture of ethyl acetate and water (25 and 5 mL, respectively), the organic phase was separated and washed with saturated aqueous NaHCO₃. The solvent was removed under reduced pressure and the crude product was purified on a pre-packed 12 g silica column (RediSep™, Isco, Inc.) using ethyl acetate as the eluent.

Yield 0.56 g (27%). Calculated for C₁₁H₁₂N₂O₂ *m/z*: 204.09, found 204.97 [M+H]⁺.

¹H NMR (400 MHz, CDCl₃) δ ppm 2.92 (t, *J*=6.3 Hz, 2 H), 3.67 (s, 3 H), 4.57 (t, *J*=6.3 Hz, 2 H), 7.36 (m, 2 H), 7.45 (m, 1 H), 7.87 (m, 1 H), 8.36 (s, 1 H).

Part B: Synthesis of 3-(1*H*-benzoimidazol-1-yl)propanoic acid

To a solution of methyl 3-(1*H*-benzoimidazol-1-yl)propanoate (0.56 g, 2.7 mmol) in methanol (0.5 mL) an aqueous solution of NaOH (2M, 0.5 mL) was added under stirring at ambient temperature. Upon consumption of the starting material (15 min), methanol was removed from the reaction mixture under reduced pressure. Aqueous HCl (1 M, 1 mL) was added followed by evaporation of the volatiles. To the residue dichloromethane (30 mL) containing triethylamine (1 mL) was added and the slurry was filtered. The filtrate was concentrated and the crude product was purified on a pre-packed 12 g silica column (RediSep™, Isco, Inc.) using 3% methanol and 1% triethylamine in dichloromethane as an eluent. Product-containing fractions were pooled, concentrated under reduced pressure, co-evaporated with ethyl acetate (3×10 mL) and dried under reduced pressure at 40 °C for 24 h.

Yield 0.34 g (65%). Calculated for C₁₀H₁₀N₂O₂ *m/z*: 190.07, found 190.91 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.81 (t, *J*=6.8 Hz, 2 H), 4.45 (t, *J*=6.8 Hz, 2 H), 7.22 (m, 2 H), 7.61 (dd, *J*=2.0, 1.0 Hz, 1 H), 7.63 (m, 1 H), 8.17 (s, 1 H).

Part C. The title compound was synthesized according to a procedure described in Example 10 starting from 3-benzoimidazol-1-yl-propanoic acid and 4-*tert*-butyl-aniline. Calculated for C₁₆H₂₃N₃O *m/z*: 321.18, found 322.1 [M+H]⁺.

Example 14**4-Benzoimidazol-1-yl-N-(4-tert-butyl-phenyl)-butyramide****Part A: Synthesis of methyl 4-(1H-benzoimidazol-1-yl)butanoate**

Methyl 4-(1H-benzoimidazol-1-yl)butanoate was prepared according to the procedure described in Example 13 (Part A) from 1H-benzoimidazole (1.21 g, 10 mmol) and methyl 4-bromobutanoate (1.3 mL, 10 mmol) in the presence of tetra-*n*-butylammonium iodide (300 mg, 0.8 mmol). Purification was performed using 2% methanol in dichloromethane.

Yield 1.41 g (65%). Calculated for $C_{12}H_{14}N_2O_2$ m/z : 218.11, found 219.98 $[M+H]^+$.

1H NMR (400 MHz, $CDCl_3$) δ ppm 2.22 (m, 2 H), 2.35 (t, $J=6.6$ Hz, 2 H), 3.67 (s, 3 H), 4.31 (t, $J=7.1$ Hz, 2 H), 7.33 (m, 2 H), 7.46 (m, 1 H), 7.83 (m, 1 H), 8.14 (s, 1 H).

Part B: Synthesis of 4-(1H-benzoimidazol-1-yl)butanoic acid

The title compound was prepared according to the procedure described in Example 13 (Part B) starting from methyl 4-(1H-benzoimidazol-1-yl)butanoate (1.41 g, 6.5 mmol).

Yield 1.1 g (54%). Calculated for $C_{11}H_{12}N_2O_2$ m/z : 204.09, found 204.91 $[M+H]^+$.

1H NMR (400 MHz, DMSO- d_6) δ ppm 2.01 (m, 2 H), 2.22 (t, $J=7.3$ Hz, 2 H), 4.26 (t, $J=7.1$ Hz, 2 H), 7.22 (m, 2 H), 7.62 (dd, $J=18.2, 8.1$ Hz, 2 H), 8.20 (s, 1 H), 12.11 (s, 1 H).

Part C. The title compound was synthesized according to a procedure described in Example 10 starting from 4-benzoimidazol-1-yl-butyric acid and 4-*tert*-butyl-aniline. Calculated for $C_{16}H_{23}N_3O$ m/z : 335.20, found 336.1 $[M+H]^+$.

Example 15**2-Benzoimidazol-1-yl-N-(2-methyl-benzothiazol-5-yl)-acetamide**

2-Methyl-benzothiazol-5-ylamine (32 mg, 0.2 mmol) and bromoacetyl bromide were added to a suspension of (*N,N*-diisopropyl)aminomethylpolystyrene resin (170 mg) in anhydrous THF (2 mL) and the reaction mixture was shaken for 4 h at ambient temperature. The resin was then filtered off. 1H-benzoimidazole (35 mg, 0.3 mmol) and potassium *tert*-butoxide (0.36 mL of 1 M solution in THF, 0.36 mmol,) were added and the mixture was stirred at 55 °C for 24 h. The crude product was purified on a preparative

LC/MS (XTerra C₈ column 19×100 mm, 0.1 M aqueous NH₄Ac/CH₃CN). The pooled fractions were lyophilized to afford 4 mg (6 %) of the title compound.

Calculated for C₁₇H₁₄N₄OS *m/z*: 322.39, found 323.0 [M+H]⁺.

5 Example 16

2-Benzoimidazol-1-yl-N-(3-trifluoromethyl-phenyl)-acetamide

A solution of potassium *tert*-butoxide (1.7 mL of 1 M solution in THF, 1.7 mmol,) was added to a solution of 1*H*-benzoimidazole (165 mg, 1.4 mmol) in anhydrous THF (3 mL).

The reaction mixture was stirred for 20 min at ambient temperature. 2-Bromo-*N*-(3-trifluoromethyl-phenyl)-acetamide (example 5 part A) was added (261 mg, 0.93 mmol) and the mixture was stirred at 55 °C for subsequent 24 h. The crude product was purified on a preparative HPLC (XTerra C₈ column 19×300 mm, 0.1 M aqueous NH₄Ac/CH₃CN). The pooled fractions were lyophilized to afford 81 mg (27 %) of the title compound.

Calculated for C₁₆H₁₂F₃N₃O *m/z*: 319.29, found 320.0 [M+H]⁺.

15 ¹H NMR (400 MHz, MeOH) δ ppm 5.2 (s, 2 H), 7.3 (m, 2 H), 7.4 (d, *J*=7.6 Hz, 1 H), 7.5 (m, 2 H), 7.7 (d, *J*=7.1 Hz, 1 H), 7.8 (d, *J*=8.6 Hz, 1 H), 8.0 (s, 1 H), 8.2 (s, 1 H).

Example 17

2-(7-Nitro-1H-benzoimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide

20 Potassium *tert*-butoxide (195 mg, 1.73 mmol,) was added to a stirred solution of 4(7)-nitro-1*H*-benzoimidazole (270 mg, 1.65 mmol) in DMF (5.5 mL). After 10 min 2-bromo-*N*-[3-(trifluoromethyl)phenyl]acetamide (466 mg, 1.65 mmol) was added and the mixture was stirred for 3 h at ambient temperature. The solvent was removed under reduced pressure and the residue was treated with ethyl acetate and 0.5 M phosphate buffer (pH 7) (25 mL of each). The organic layer was separated, washed with brine (5 mL), dried over anhydrous Na₂SO₄ and concentrated to leave a mixture of 4- and 7-nitro regioisomers. Separation of the mixture was performed on preparative HPLC (XTerra C₈ column 19×300 mm, 0.1 M NH₄OAc/CH₃CN). Product-containing fractions were pooled and lyophilised affording the pure individual regioisomers.

30 The major product: 2-(4-nitro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide was obtained in 73% (435 mg) yield.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 5.36 (s, 2 H), 7.45 (m, 2 H), 7.58 (t, *J*=7.8 Hz, 1 H), 7.77 (d, *J*=8.6 Hz, 1 H), 8.06 (bs, 2 H), 8.08 (s, 1 H), 8.55 (s, 1 H), 10.83 (s, 1 H).

The title compound was obtained as a minor product (45.3 mg, 8%). Calculated for C₁₆H₁₁F₃N₄O₃ *m/z*: 364.08, found 365.03 [M+H]⁺.

¹H NMR (400 MHz, CD₃CN) δ ppm 5.43 (s, 2 H), 7.43 (m, 2 H), 7.56 (t, *J*=8.1 Hz, 1 H), 7.71 (d, *J*=8.1 Hz, 1 H), 7.98 (s, 1 H), 8.03 (dd, *J*=8.1, 0.76 Hz, 1 H), 8.15 (dd, *J*=7.8, 1.0 Hz, 1 H), 8.45 (s, 1 H), 10.76 (s, 1 H).

Example 18

2-(4-Amino-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide

2-(4-Nitro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide (60 mg, 0.17 mmol) (see Example 17) was dissolved in ethanol (1.44 mL) and tin(II) chloride (192 mg, 0.85 mmol) was added. The reaction mixture was stirred at 70 °C for 16 h and then poured onto a mixture of ice and saturated aqueous NaHCO₃ (20 mL). The basic solution was extracted with ethyl acetate (3×10 mL), washed with brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated. The purification of the crude product was performed by preparative HPLC (XTerra C₈ column 19×300 mm, 0.1 M NH₄OAc/CH₃CN). Product-containing fractions were pooled and lyophilised affording the title compound (11.3 mg, 20%).

Calculated for C₁₆H₁₃F₃N₄O *m/z*: 334.10, found 335.09 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 5.07 (s, 2 H), 5.24 (s, 2 H), 6.37 (dd, *J*=7.6, 0.8 Hz, 1 H), 6.64 (dd, *J*=8.0, 0.63 Hz, 1 H), 6.90 (t, *J*=7.8 Hz, 1 H), 7.42 (d, *J*=7.8 Hz, 1 H), 7.57 (t, *J*=8.0 Hz, 1 H), 7.77 (m, 1 H), 7.99 (s, 1 H), 8.06 (s, 1 H), 10.74 (s, 1 H).

Example 19

2-(6,7-Difluoro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide

To a suspension of 4,5-difluoro-1*H*-benzoimidazole (20 mg, 0.13 mmol) in toluene (260 μL), triethylamine (18 μL, 0.13 mmol) and 2-bromo-*N*-[3-(trifluoromethyl)phenyl]acetamide (37 mg, 0.13 mmol) were added. The reaction mixture was microwave-irradiated in a sealed vial at 120 °C for 30 min. The vial was cooled, opened and the contents dissolved in 20 mL ethyl acetate. The solution was washed with

water (5 mL), saturated aqueous NaHCO_3 (5 mL) and brine (5 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. Purification of the crude product was performed on flash silica column using neat ethyl acetate to yield the title compound (11.3 mg, 25%). Calculated for $\text{C}_{16}\text{H}_{10}\text{F}_5\text{N}_3\text{O}$ m/z : 355.07, found 355.84 $[\text{M}+\text{H}]^+$.

5 ^1H NMR (400 MHz, MeOD) δ ppm 5.31 (s, 2 H), 7.20 (ddd, $J=11.4, 9.0, 7.5$ Hz, 1 H), 7.40 (d, $J=7.8$ Hz, 1 H), 7.47 (ddd, $J=8.9, 3.7, 1.3$ Hz, 1 H), 7.52 (t, $J=8.1$ Hz, 1 H), 7.79 (d, $J=8.8$ Hz, 1 H), 7.96 (s, 1 H), 8.20 (s, 1 H).

Example 20

10 2-(5-fluoro-1H-benzoimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide and 2-(6-fluoro-1H-benzoimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide (mixture of 5- and 6-regioisomers)

Synthesis was performed as described in Example 19 using 5(6)-fluoro-1H-benzoimidazole (68 mg, 0.5 mmol). Yield 28 mg (17%). Calculated for $\text{C}_{16}\text{H}_{11}\text{F}_4\text{N}_3\text{O}$ m/z :
15 337.08, found 337.83 $[\text{M}+\text{H}]^+$.

Example 21

2-(1H-benzoimidazol-1-yl)-N-heptylacetamide

O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (80 mg,
20 0.21 mmol) was added under stirring to a solution of 1H-benzoimidazol-1-ylacetic acid triethylammonium salt (55.5 mg, 0.2 mmol) and N-methyl morpholine (66 μL , 0.6 mmol) in acetonitrile (1 mL). After 5 min 1-heptylamine (30 μL , 0.2 mmol) was added and mixture was stirred at ambient temperature for 3 h. The solvent was evaporated, the residue was dissolved in ethyl acetate (15 mL) and extracted with saturated aqueous NaHCO_3 (5
25 mL) and brine (5 mL) then dried over anhydrous Na_2SO_4 and concentrated. Purification of the crude product was performed by preparative HPLC (XTerra C_8 column 19 \times 300 mm, 0.1 M $\text{NH}_4\text{OAc}/\text{CH}_3\text{CN}$). Product-containing fractions were pooled and lyophilised affording the title compound (43.7 mg, 80%). Calculated for $\text{C}_{16}\text{H}_{23}\text{N}_3\text{O}$ m/z : 273.18, found 274.03 $[\text{M}+\text{H}]^+$.

30 ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 0.85 (m, 3 H), 1.26 (m, 8 H), 1.41 (m, 2 H), 3.07 (m, 2 H), 4.88 (s, 2 H), 7.20 (m, 2 H), 7.42 (m, 1 H), 7.64 (m, 1 H), 8.14 (s, 1 H), 8.27 (t, $J=5.6$ Hz, 1 H).

Example 22***2-(5-Fluoro-1H-indol-3-yl)-N-[3-(trifluoromethyl)phenyl]acetamide***

The title compound was synthesized in 57% yield (38.5 mg) according to a procedure described in Example 21 starting from (5-fluoro-1H-indol-3-yl)-acetic acid and 3-trifluoromethyl-aniline.

Calculated for $C_{16}H_{23}N_3O$ m/z : 336.09, found 336.88 $[M+H]^+$.

1H NMR (400 MHz, DMSO- d_6) δ 3.73 (s, 2 H), 6.91 (m, 1 H), 7.34 (m, 4 H), 7.53 (t, $J=8.1$ Hz, 1 H), 7.78 (d, $J=8.1$ Hz, 1 H), 8.09 (s, 1 H), 10.42 (s, 1 H), 11.03 (s, 1 H).

Example 23***2-(1-Methyl-1H-indol-3-yl)-N-[3-(trifluoromethyl)phenyl]acetamide***

The title compound was synthesized in 62% yield (41.1 mg) according to a procedure described in Example 21 starting from (1-methyl-1H-indol-3-yl)-acetic acid and 3-trifluoromethyl-aniline.

Calculated for $C_{16}H_{23}N_3O$ m/z : 332.11, found 332.89 $[M+H]^+$.

1H NMR (400 MHz, DMSO- d_6) δ ppm 3.74 (s, 2 H), 3.75 (s, 3 H), 7.01 (m, 1 H), 7.14 (m, 1 H), 7.25 (s, 1 H), 7.38 (t, $J=8.1$ Hz, 2 H), 7.53 (t, $J=7.8$ Hz, 1 H), 7.60 (d, $J=8.1$ Hz, 1 H), 7.79 (d, $J=8.6$ Hz, 1 H), 8.10 (s, 1 H), 10.43 (s, 1 H).

Pharmacology

DRGs were dissected out from adult Sprague Dawley rats (100-300 gr), and placed on ice in L15 Leibovitz medium. The ganglia were enzyme treated with Collagenase 80U/ml+ Dispase 34 U/ml dissolved in DMEM +5% serum, overnight at 37 °C. The next day, cells were triturated with fire polished pasteur pipettes, and seeded in the center of 58 mm diameter Nunc cell dishes coated with Poly-D Lysine (1 mg/mL). The DRGs were cultured in a defined medium without foetal bovine serum, containing Dulbecco's MEM / NUT MIX F-12 (1:1) without L-glutamine but with pyridoxine, 6 mg/mL D(+)-Glucose, 100 μ g/mL apo-transferrin, 1 mg/mL BSA, 20 μ g/mL insulin, 2 mM L-glutamine, 50 IU/ mL Penicillin, 50 μ g / mL Streptomycin and 0.01 μ g/mL NGF-7S.

When the cells had grown for 2 days up to 4 weeks, the experiments were done. Cells were chosen based on size and presence of neurites. Small cells with long processes were used for recording (most likely to be C neurons, with native VR1 receptors).

- 5 The cells were recorded with conventional whole cell voltage clamp patch clamp, using the following solutions (calcium ion free):

The extracellular solution comprised (in mM): NaCl 137, KCl 5, $\text{MgCl}_2 \cdot \text{H}_2\text{O}$ 1.2, HEPES 10, Glucose 10, EGTA 5, Sucrose 50, pH to 7.4 with NaOH.

- The intracellular solution comprised K-gluconate 140, NaCl 3, $\text{MgCl}_2 \cdot \text{H}_2\text{O}$ 1.2, HEPES 10, EGTA 1, pH to 7.2 with KOH. When the cells were penetrated with suction, a puff of capsaicin (500 nM) was used to determine if the cell expressed VR1 receptor. If not, a new cell was chosen. If yes, then the compounds were added in increasing doses before the capsaicin pulse (500 nM), to determine an IC_{50} value.
- 10

15 **List of abbreviations**

VR1	vanilloid receptor 1
IBS	irritable bowel syndrome
IBD	inflammatory bowel disease
GERD	gastro-esophageal reflux disease
20 DRG	Dorsal Root Ganglion
BSA	Bovine Serum Albumin
HEPES	4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
EGTA	Ethylene glycol-bis(2-aminoethylether)- <i>N,N,N',N'</i> -tetraacetic acid
DMEM	Dulbeccos Modified Eagle's Medium


25 **Results**

Typical IC_{50} values as measured in the assays described above are 10 μM or less. In one aspect of the invention the IC_{50} is below 500 nM. In another aspect of the invention the IC_{50} is below 100 nM. In a further aspect of the invention the IC_{50} is below 10 nM.

30

CLAIMS

1. A compound having the formula I



5 wherein:

R^1 is H, NO_2 , NH_2 , halo, NR^6R^7 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} haloalkylO, C_{1-6} alkylOC $_{0-6}$ alkyl, $\text{R}^6\text{OC}_{1-6}$ alkyl, R^6CO , CO_2R^6 or CONR^6R^7 ;

m is 1, 2, 3 or 4;

R^2 is H, NO_2 , NH_2 , halo, NR^6R^7 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl,

10 C_{1-6} haloalkylO, C_{1-6} alkylOC $_{0-6}$ alkyl, $\text{R}^6\text{OC}_{1-6}$ alkyl, R^6CO , CO_2R^6 or CONR^6R^7 ;

X, Y and Z are each independently C, CR^6 , N or NR^6 ;

R^3 is H or C_{0-4} alkyl;

n is 0, 1, 2 or 3;

R^4 is H or C_{0-4} alkyl;

15 R^5 is H, C_{1-10} alkyl, C_{5-6} aryl, C_{3-7} cycloalkyl, C_{5-6} heteroaryl, whereby any aryl or cycloalkyl may be fused with heteroaryl, C_{3-7} cycloalkyl or C_{3-7} heterocycloalkyl;

and R^4 and R^5 may be substituted with one or more A; and

A is H, OH, NO_2 , NH_2 , CO, O(CO), halo, C_{1-6} alkyl, NR^6R^7 , C_{1-6} haloalkyl,

C_{1-6} alkylOC $_{0-6}$ alkyl, $\text{R}^6\text{OC}_{1-6}$ alkyl, R^6CO , CO_2R^6 or CONR^6R^7 ;

20 R^6 and R^7 are each independently H or C_{1-6} alkyl;

or salts, solvates or solvated salts thereof,

with the proviso the compound is not 2-Indol-1-yl-*N*-(3-trifluoromethyl-phenyl)-acetamide and 2-(7-Nitro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide.

25 2. The compound according to claim 1 wherein R^1 is H, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl;

m is 1 or 2;

R^2 is H, NO_2 , NH_2 , halo, NR^6R^7 , C_{1-6} alkyl or C_{1-6} haloalkyl;

X, Y and Z are each independently C, N or NR^6 ;

R^3 is H or C_{0-4} alkyl;

n is 0, 1 or 2;

5 R^4 is H;

R^5 is H, C_{1-10} alkyl, C_{5-6} aryl, whereby any aryl may be fused with heteroaryl;

and R^4 and R^5 may be substituted with one or more A; and

A is H, OH, halo, C_{1-6} alkyl, NR^6R^7 , C_{1-6} haloalkyl or C_{1-6} alkyl OC_{0-6} alkyl;

R^6 and R^7 are each independently H or C_{1-6} alkyl.

10

3. The compound according to any one of claims 1 or 2 wherein R^1 is selected from the group consisting of H, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl and C_{1-6} haloalkyl and m is 1 or 2.

15 4. The compound according to any one of claims 1 to 3 wherein R^2 is H, NO_2 , NH_2 or halo.

5. The compound according to any one of claims 1 to 4 wherein X and Z are N and Y is CR^6 .

20 6. The compound according to any one of claims 1 to 5 wherein R^4 is H and R^5 is selected from the group consisting of H, C_{1-10} alkyl and C_{5-6} aryl, whereby any aryl may be fused with heteroaryl.


7. The compounds selected from the group consisting of

- 25 2-Benzoimidazol-1-yl-N-(3-trifluoromethyl-phenyl)-propionamide,
2-Benzoimidazol-1-yl-N-(3-chloro-4-fluoro-phenyl)-acetamide,
2-Benzoimidazol-1-yl-N-(3-fluoro-4-methyl-phenyl)-acetamide,
2-Benzoimidazol-1-yl-N-(3,4-difluoro-phenyl)-acetamide,
2-(4-Methyl-1H-benzoimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
30 2-(4,5-Difluoro-benzoimidazol-1-yl)-N-(3-trifluoromethyl-phenyl)-acetamide,
2-(6,7-difluoro-benzoimidazol-1-yl)-N-(3-trifluoromethyl-phenyl)-acetamide,
2-(4,5-difluoro-benzoimidazol-1-yl)-N-(3-trifluoromethyl-phenyl)-acetamide,

- 2-Benzoimidazol-1-yl-*N*-(3-dimethylamino-phenyl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(4-tert-butyl-phenyl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(3-trifluoromethyl-benzyl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(4-chloro-benzyl)-acetamide,
5 2-(1*H*-Benzoimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
3-Benzoimidazol-1-yl-*N*-(4-tert-butyl-phenyl)-propionamide,
4-Benzoimidazol-1-yl-*N*-(4-tert-butyl-phenyl)-butyramide,
2-Benzoimidazol-1-yl-*N*-(2-methyl-benzothiazol-5-yl)-acetamide,
2-Benzoimidazol-1-yl-*N*-(3-trifluoromethyl-phenyl)-acetamide,
10 2-(4-Amino-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(6,7-Difluoro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(5-fluoro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(6-fluoro-1*H*-benzoimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(1*H*-benzoimidazol-1-yl)-*N*-heptylacetamide,
15 2-(5-Fluoro-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, and
2-(1-Methyl-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
or salts, solvates or solvated salts thereof.

8. A processes for the preparation of the compound according to claim 1, wherein R^1 to R^4 , are defined as in claim 1, comprising;


Method A



- 5 whereby the target compound of formula Ia is obtained from the acid of formula IIa or its deprotonated form IIb, *via* its conversion into an activated form and further treatment with an appropriate amine NHR^4R^5 ,

or,


Method B



10 wherein, the target compound of formula Ia is obtained from an alkylbromide of formula V and an appropriate benzimidazole.

9. A process for purifying mixtures of regioisomers of the compound of formula I, according to claim 1, comprising;

Method C



- 5 wherein 4-nitrobenzoimidazole is converted to a mixture of 4-nitro- and 7-nitro-regioisomers of formula Ib and Ic, or the nitro derivative is converted to the corresponding amino derivative of formula Id using an appropriate reducing agent.

10. The compound according to any one of claims 1 to 7, for use in therapy.

11. Use of the compound according to any one of claims 1 to 7, in treatment of VR1 mediated disorders.

12. The use according to claim 11 for treatment of acute and chronic pain disorders.

13. The use according to claim 11 for treatment of acute and chronic inflammatory pain.

14. The use according to claim 11 for treatment of indications selected from the group consisting of arthritis, fibromyalgia, low back pain, post-operative pain, visceral pains like chronic pelvic pain, cystitis, IBS, pancreatitis, sciatica, diabetic neuropathy, HIV
5 neuropathy, asthma, cough, IBD, psoriasis, gastro-esophageal reflux disease (GERD), emesis, urinary incontinence and hyperactive bladder.

15. Use of the compound of formula I according to any one of claims 1 to 7, in the manufacture of a medicament for the treatment of VR1 mediated disorders and for the
10 treatment of acute and chronic pain disorders and acute and chronic inflammatory pain.

16. A method of treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders and acute and chronic inflammatory pain, comprising administering to a mammal, including man in need of such treatment, a therapeutically
15 effective amount of the compound of formula I, according to any one of claims 1 to 7.

17. A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of formula I, according to any one of claims 1 to 7, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert
20 carriers.

18. The pharmaceutical formulation according to claim 17, for use in the treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders and acute and chronic inflammatory pain.
25

19. Use of 2-Indol-1-yl-N-(3-trifluoromethyl-phenyl)-acetamide and 2-(7-Nitro-1H-benzoimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide, in the manufacture of a medicament for the treatment of VR1 mediated disorders and for the treatment of acute and chronic pain disorders and acute and chronic inflammatory pain.
30

20. Use of compounds

2-bromo-*N*-(3-trifluoromethyl-phenyl)-propionamide,

benzoimidazol-1-yl-acetic acid *tert*-butyl ester,

3-carboxymethyl-3*H*-benzoimidazol-1-ium trifluoro-acetate,

5 2-bromo-*N*-(3-trifluoromethyl-phenyl)-acetamide,

Synthesis of 4-methyl-1*H*-benzoimidazole,

2-Bromo-*N*-(3-dimethylamino-phenyl)-acetamide,

methyl 3-(1*H*-benzoimidazol-1-yl)propanoate ,

3-(1*H*-benzoimidazol-1-yl)propanoic acid,

10 methyl 4-(1*H*-benzoimidazol-1-yl)butanoate, and


4-(1*H*-benzoimidazol-1-yl)butanoic acid,

as intermediates in the preparation of compounds suited for the treatment of VR1 mediated disorders.

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
211

ABSTRACT

The present invention relates to new compounds of formula I,



- 5 wherein R^1 to R^5 are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.